Maternal Mental Health Market Size, Demand, Global Trends

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Maternal Mental Health Market Size Analysis

Global Maternal Mental Health Market Introduction
By Disease Indication
1. Introduction
  1. Disease Indication By Value
2. Postpartum Depression
  1. By Value
3. Dysthymia
  1. By Value
4. Pregnancy and Postpartum General Anxiety
  1. By Value
5. Pregnancy and Postpartum OCD
  1. By Value
6. Birth-Related PTSD
  1. By Value
7. Others
  1. By Value
By Treatment
1. Introduction
  1. Treatment By Value
2. Antidepressants
  1. By Value
  2. Selective serotonin reuptake inhibitors (SSRIs)
    1. Selective serotonin reuptake inhibitors (SSRIs) By Value
  3. Tricyclic antidepressants (TCAs)
    1. Tricyclic antidepressants (TCAs) By Value
  4. Others
    1. Others By Value
3. Interpersonal Psychotherapy (IPT)
  1. By Value
4. Cognitive Behavioral Therapy (CBT)
  1. By Value
5. Others
  1. By Value

North America Market Analysis

Introduction
By Disease Indication
1. Introduction
  1. Disease Indication By Value
2. Postpartum Depression
  1. By Value
3. Dysthymia
  1. By Value
4. Pregnancy and Postpartum General Anxiety
  1. By Value
5. Pregnancy and Postpartum OCD
  1. By Value
6. Birth-Related PTSD
  1. By Value
7. Others
  1. By Value
By Treatment
1. Introduction
  1. Treatment By Value
2. Antidepressants
  1. By Value
  2. Selective serotonin reuptake inhibitors (SSRIs)
    1. Selective serotonin reuptake inhibitors (SSRIs) By Value
  3. Tricyclic antidepressants (TCAs)
    1. Tricyclic antidepressants (TCAs) By Value
  4. Others
    1. Others By Value
3. Interpersonal Psychotherapy (IPT)
  1. By Value
4. Cognitive Behavioral Therapy (CBT)
  1. By Value
5. Others
  1. By Value
U.S.
1. By Disease Indication
  1. Introduction
    1. Disease Indication By Value
  2. Postpartum Depression
    1. By Value
  3. Dysthymia
    1. By Value
  4. Pregnancy and Postpartum General Anxiety
    1. By Value
  5. Pregnancy and Postpartum OCD
    1. By Value
  6. Birth-Related PTSD
    1. By Value
  7. Others
    1. By Value
2. By Treatment
  1. Introduction
    1. Treatment By Value
  2. Antidepressants
    1. By Value
    2. Selective serotonin reuptake inhibitors (SSRIs)
      1. Selective serotonin reuptake inhibitors (SSRIs) By Value
    3. Tricyclic antidepressants (TCAs)
      1. Tricyclic antidepressants (TCAs) By Value
    4. Others
      1. Others By Value
  3. Interpersonal Psychotherapy (IPT)
    1. By Value
  4. Cognitive Behavioral Therapy (CBT)
    1. By Value
  5. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Disease Indication
1. Introduction
  1. Disease Indication By Value
2. Postpartum Depression
  1. By Value
3. Dysthymia
  1. By Value
4. Pregnancy and Postpartum General Anxiety
  1. By Value
5. Pregnancy and Postpartum OCD
  1. By Value
6. Birth-Related PTSD
  1. By Value
7. Others
  1. By Value
By Treatment
1. Introduction
  1. Treatment By Value
2. Antidepressants
  1. By Value
  2. Selective serotonin reuptake inhibitors (SSRIs)
    1. Selective serotonin reuptake inhibitors (SSRIs) By Value
  3. Tricyclic antidepressants (TCAs)
    1. Tricyclic antidepressants (TCAs) By Value
  4. Others
    1. Others By Value
3. Interpersonal Psychotherapy (IPT)
  1. By Value
4. Cognitive Behavioral Therapy (CBT)
  1. By Value
5. Others
  1. By Value
U.K.
1. By Disease Indication
  1. Introduction
    1. Disease Indication By Value
  2. Postpartum Depression
    1. By Value
  3. Dysthymia
    1. By Value
  4. Pregnancy and Postpartum General Anxiety
    1. By Value
  5. Pregnancy and Postpartum OCD
    1. By Value
  6. Birth-Related PTSD
    1. By Value
  7. Others
    1. By Value
2. By Treatment
  1. Introduction
    1. Treatment By Value
  2. Antidepressants
    1. By Value
    2. Selective serotonin reuptake inhibitors (SSRIs)
      1. Selective serotonin reuptake inhibitors (SSRIs) By Value
    3. Tricyclic antidepressants (TCAs)
      1. Tricyclic antidepressants (TCAs) By Value
    4. Others
      1. Others By Value
  3. Interpersonal Psychotherapy (IPT)
    1. By Value
  4. Cognitive Behavioral Therapy (CBT)
    1. By Value
  5. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Disease Indication
1. Introduction
  1. Disease Indication By Value
2. Postpartum Depression
  1. By Value
3. Dysthymia
  1. By Value
4. Pregnancy and Postpartum General Anxiety
  1. By Value
5. Pregnancy and Postpartum OCD
  1. By Value
6. Birth-Related PTSD
  1. By Value
7. Others
  1. By Value
By Treatment
1. Introduction
  1. Treatment By Value
2. Antidepressants
  1. By Value
  2. Selective serotonin reuptake inhibitors (SSRIs)
    1. Selective serotonin reuptake inhibitors (SSRIs) By Value
  3. Tricyclic antidepressants (TCAs)
    1. Tricyclic antidepressants (TCAs) By Value
  4. Others
    1. Others By Value
3. Interpersonal Psychotherapy (IPT)
  1. By Value
4. Cognitive Behavioral Therapy (CBT)
  1. By Value
5. Others
  1. By Value
China
1. By Disease Indication
  1. Introduction
    1. Disease Indication By Value
  2. Postpartum Depression
    1. By Value
  3. Dysthymia
    1. By Value
  4. Pregnancy and Postpartum General Anxiety
    1. By Value
  5. Pregnancy and Postpartum OCD
    1. By Value
  6. Birth-Related PTSD
    1. By Value
  7. Others
    1. By Value
2. By Treatment
  1. Introduction
    1. Treatment By Value
  2. Antidepressants
    1. By Value
    2. Selective serotonin reuptake inhibitors (SSRIs)
      1. Selective serotonin reuptake inhibitors (SSRIs) By Value
    3. Tricyclic antidepressants (TCAs)
      1. Tricyclic antidepressants (TCAs) By Value
    4. Others
      1. Others By Value
  3. Interpersonal Psychotherapy (IPT)
    1. By Value
  4. Cognitive Behavioral Therapy (CBT)
    1. By Value
  5. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Disease Indication
1. Introduction
  1. Disease Indication By Value
2. Postpartum Depression
  1. By Value
3. Dysthymia
  1. By Value
4. Pregnancy and Postpartum General Anxiety
  1. By Value
5. Pregnancy and Postpartum OCD
  1. By Value
6. Birth-Related PTSD
  1. By Value
7. Others
  1. By Value
By Treatment
1. Introduction
  1. Treatment By Value
2. Antidepressants
  1. By Value
  2. Selective serotonin reuptake inhibitors (SSRIs)
    1. Selective serotonin reuptake inhibitors (SSRIs) By Value
  3. Tricyclic antidepressants (TCAs)
    1. Tricyclic antidepressants (TCAs) By Value
  4. Others
    1. Others By Value
3. Interpersonal Psychotherapy (IPT)
  1. By Value
4. Cognitive Behavioral Therapy (CBT)
  1. By Value
5. Others
  1. By Value
UAE
1. By Disease Indication
  1. Introduction
    1. Disease Indication By Value
  2. Postpartum Depression
    1. By Value
  3. Dysthymia
    1. By Value
  4. Pregnancy and Postpartum General Anxiety
    1. By Value
  5. Pregnancy and Postpartum OCD
    1. By Value
  6. Birth-Related PTSD
    1. By Value
  7. Others
    1. By Value
2. By Treatment
  1. Introduction
    1. Treatment By Value
  2. Antidepressants
    1. By Value
    2. Selective serotonin reuptake inhibitors (SSRIs)
      1. Selective serotonin reuptake inhibitors (SSRIs) By Value
    3. Tricyclic antidepressants (TCAs)
      1. Tricyclic antidepressants (TCAs) By Value
    4. Others
      1. Others By Value
  3. Interpersonal Psychotherapy (IPT)
    1. By Value
  4. Cognitive Behavioral Therapy (CBT)
    1. By Value
  5. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Disease Indication
1. Introduction
  1. Disease Indication By Value
2. Postpartum Depression
  1. By Value
3. Dysthymia
  1. By Value
4. Pregnancy and Postpartum General Anxiety
  1. By Value
5. Pregnancy and Postpartum OCD
  1. By Value
6. Birth-Related PTSD
  1. By Value
7. Others
  1. By Value
By Treatment
1. Introduction
  1. Treatment By Value
2. Antidepressants
  1. By Value
  2. Selective serotonin reuptake inhibitors (SSRIs)
    1. Selective serotonin reuptake inhibitors (SSRIs) By Value
  3. Tricyclic antidepressants (TCAs)
    1. Tricyclic antidepressants (TCAs) By Value
  4. Others
    1. Others By Value
3. Interpersonal Psychotherapy (IPT)
  1. By Value
4. Cognitive Behavioral Therapy (CBT)
  1. By Value
5. Others
  1. By Value
Brazil
1. By Disease Indication
  1. Introduction
    1. Disease Indication By Value
  2. Postpartum Depression
    1. By Value
  3. Dysthymia
    1. By Value
  4. Pregnancy and Postpartum General Anxiety
    1. By Value
  5. Pregnancy and Postpartum OCD
    1. By Value
  6. Birth-Related PTSD
    1. By Value
  7. Others
    1. By Value
2. By Treatment
  1. Introduction
    1. Treatment By Value
  2. Antidepressants
    1. By Value
    2. Selective serotonin reuptake inhibitors (SSRIs)
      1. Selective serotonin reuptake inhibitors (SSRIs) By Value
    3. Tricyclic antidepressants (TCAs)
      1. Tricyclic antidepressants (TCAs) By Value
    4. Others
      1. Others By Value
  3. Interpersonal Psychotherapy (IPT)
    1. By Value
  4. Cognitive Behavioral Therapy (CBT)
    1. By Value
  5. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Maternal Mental Health Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Canopie
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Brightside Health Inc.
March of Dimes
Mammha
Viatris Inc.
GSK plc.
Alembic Pharmaceuticals Limited
Mallinckrodt
Sage Therapeutics, Inc.
Bausch Health Companies Inc.
Magellan Health, Inc.
Pfizer Inc.
Therapy Mama
AstraZeneca
Eli Lilly and Company

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment